New Stock News | ProLife Pharma Submits Second Application to Hong Kong Stock Exchange

According to a disclosure from the Hong Kong Stock Exchange on August 31, PuraPharm (Jiangsu) Co., Ltd. (referred to as: PuraPharm) has submitted a listing application to the main board of the Hong Kong Stock Exchange, with CITIC SEC as its sole sponsor. The company had previously submitted a listing application to the Hong Kong Stock Exchange on February 13. The prospectus shows that PuraPharm is a biopharmaceutical company specializing in antimicrobial peptides (AMP), established in April 2009, focusing on two core therapeutic areas: anti-infection and metabolic diseases. As of the last practicable date (August 24, 2026), the company has (i) a core product PL-5 (Pelagib), which is a topical spray product for the treatment of secondary infections of first or superficial second-degree burn wounds caused by Staphylococcus epidermidis, Staphylococcus aureus, or Acinetobacter baumannii (secondary infections of burn wounds) and diabetic foot infections (DFI); and (ii) three other candidate drugs in its pipeline.